UiPath (PATH) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
UiPath is a buy due to its strong recurring revenue, high gross margins, and horizontal product relevance across industries, despite recent sales slowdowns. The company has implemented strategic changes, including leadership shifts, workforce restructuring, and new product launches, to address growth and execution challenges. UiPath's valuation is attractive at
On October 3, 2024, Hitesh Ramani, the Chief Accounting Officer of UiPath Inc (PATH, Financial), sold 25,000 shares of the company at a price of $12 per share. The transaction was documented in a recent SEC Filing.
UiPath (PATH) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Morgan Stanley analysts think UiPath stock could return 212% by September 2025, and Ark Invest analysts believe Roku shares could surge 712% by December 2025. UiPath is the market leader in robotic process automation software, and co-founder Daniel Dines was recently reappointed CEO to reinvigorate growth.
A customer-centric approach, coupled with product innovation using GenAI, benefits PATH.
UiPath has struggled this year as its growth rate has been slowing down and it's nowhere near posting a profit. The consensus analyst price target for the stock is nearly $18, suggesting a good amount of upside for investors.
UiPath (PATH) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
The market for robotic process automation should expand dramatically. UiPath -- a key player in this cutting-edge field -- has felt some hiccups lately.
PATH has faced near-term challenges, but shows promise due to its growing customer base, healthy balance sheet, and recent share repurchase authorization. Despite the mixed earnings and decelerating ARR growth, the raised FY2025 guidance and new AI product releases in Q3'24 offer potential for renewed growth opportunities. PATH's valuation remains attractive with a FWD PEG non-GAAP ratio of 1.16x, compared to its automation/AI SaaS peers.
The robotic process-automation industry that UiPath pioneered is growing rapidly. UiPath has been losing market share to C3.ai and Microsoft.
UiPath reported solid Q2 results following its disastrous Q1 report. The company is seeing strong renewal rates and net dollar retention.